title: Multicenter phase II trial of brequinar sodium in patients with advanced melanoma.
abstract: Seventeen patients with advanced melanoma and no prior exposure to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given at a median weekly dose of 1200 mg/m2 intravenously. In 14 patients evaluable for efficacy, there were no objective responses. The toxicity was moderate. We conclude that, at this dose and schedule, brequinar has no activity in advanced melanoma.
authors.affiliation: University of Michigan, Ann Arbor.
authors.forename: R
authors.initials: R
authors.lastname: Natale
authors.forename: R
authors.initials: R
authors.lastname: Wheeler
authors.forename: M
authors.initials: M
authors.lastname: Moore
authors.forename: B
authors.initials: B
authors.lastname: Dallaire
authors.forename: W
authors.initials: W
authors.lastname: Lynch
authors.forename: R
authors.initials: R
authors.lastname: Carlson
authors.forename: A
authors.initials: A
authors.lastname: Grillo-Lopez
authors.forename: J
authors.initials: J
authors.lastname: Gyves
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011798:Quinaldines
chemical_list: D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; C046943:brequinar; D011798:Quinaldines